January - March 2022, Volume 18, Issue 1

Zhang Y, Zou W, Zhu X, Jiang L, Gui C, Fan Q, Tu Y, Chen J

Updated Understanding of the Molecular Targets of Radioiodine in Differentiated Thyroid Cancer

Acta Endo (Buc) 2022, 18 (1): 86-92
doi: 10.4183/aeb.2022.86

Radioactive iodine (RAI) therapy is a mainstay adjuvant treatment for thyroid cancer. Administration of RAI therapy after total or near-total thyroidectomy has shown a survival advantage in numerous properly selected patients. However, the role of RAI therapy after reoperation for persistent or recurrent differentiated thyroid carcinomas (DTCs) is unclear. One reason may be the possible downregulation of the I- transport system after primary surgery. RAI is transported by the sodium iodide symporter (NIS), PENDRIN, anoctamin 1 (ANO1) and cystic fibrosis transmembrane conductance regulator (CFTR) and emits β particles that destroy follicular cells. The identification of pathways of iodide (I-) transport has allowed use of the transport system to render tumours susceptible to RAI treatment via gene therapy. This review focuses on the effect of RAI therapy in follicular cell-derived thyroid cancers and offers potential novel targets that enable improved radioiodine uptake and thus an improved prognosis of thyroid cancer.

Keywords: Radioactive iodine (RAI), thyroid cancer, iodine transport system, I- uptake

Correspondence: Jian Chen MD, Hubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, 430079, China, E-mail: slzyq238@163.com